BenzingaOctober 23, 2026 at 3:10 AM NY4 Days Ago
Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14
Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
